Literature DB >> 11281347

The renoprotective effect of combined antihypertensive drugs.

L Del Vecchio1, F Locatelli.   

Abstract

In recent years, a target blood pressure (BP) of at least 125/75 mmHg has been sought in order to reduce the rate of progression of chronic renal failure (CRF) and cardiovascular mortality. Some antihypertensive agents, such as ACE inhibitors, calcium channel blockers and angiotensin receptor antagonists (and perhaps endothelin converting enzyme inhibitors and endothelin antagonists), may also reduce CRF progression because they block some of the pathogenetic mechanisms involved in renal damage. Although this effect seems to be partially independent of BP reduction, it is still not clear whether these drugs are really superior to other antihypertensive agents when low BP is achieved. However, the possibility that combination treatments with some of these drugs may confer additive or even synergistic renoprotective effects other than BP control is not only fascinating, but also important because multidrug antihypertensive regimens are required anyway to manage BP adequately in the majority of patients with CRF.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11281347

Source DB:  PubMed          Journal:  J Nephrol        ISSN: 1121-8428            Impact factor:   3.902


  3 in total

1.  Add-on therapy with angiotensin II receptor 1 blocker in children with chronic kidney disease already treated with angiotensin-converting enzyme inhibitors.

Authors:  Mieczysław Litwin; Ryszard Grenda; Joanna Sladowska; Jolanta Antoniewicz
Journal:  Pediatr Nephrol       Date:  2006-08-15       Impact factor: 3.714

2.  Evaluation of blood pressure reduction response and responder characteristics to fixed-dose combination treatment of amlodipine and losartan: a post hoc analysis of pooled clinical trials.

Authors:  Sreevalsa Unniachan; David Wu; Srinivasan Rajagopalan; Mary E Hanson; Kenji P Fujita
Journal:  J Clin Hypertens (Greenwich)       Date:  2014-08-07       Impact factor: 3.738

3.  Adjunctive treatment with moxonidine versus nitrendipine for hypertensive patients with advanced renal failure: a cost-effectiveness analysis.

Authors:  Kavi J Littlewood; Wolfgang Greiner; Dominique Baum; York Zoellner
Journal:  BMC Nephrol       Date:  2007-07-24       Impact factor: 2.388

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.